Access the world’s leading research and late-breaking news on this rapidly evolving health emergency.
A global health emergency can occur without warning, as we are currently experiencing with the rapidly-spreading coronavirus outbreak.
As scientists attempt to develop vaccines and treatments as quickly as possible to meet the increasing needs of those affected, medical researchers and healthcare professionals are working tirelessly to better understand and combat the disease. We are here to help.
Our team at Clarivate has assembled a collection of valuable tools and resources to help medical researchers, policymakers, journalists and healthcare professionals quickly and easily access the world’s leading research and late-breaking news on this evolving health emergency, including:
- Real-time updates
A resource center offering the latest coronavirus news culled from Clarivate’s data and insight tools, including Cortellis, Web of Science™, and BioWorld. These cover every stage of the fight against the coronavirus – from historical literature on all strains going back decades, to drug discovery and clinical development, regulatory submission, commercialization and patents. You can visit the website here.
- The “Disease Insights: Coronaviruses” disease brief
This comprehensive report offers a solid foundation to start – or progress – further research and analysis into the coronaviruses, including causes and symptoms to epidemiology, morbidity and mortality to transmission, treatment and prevention. Download the complimentary report here.
- Complimentary access to Cortellis Drug Discovery Intelligence
Access existing coronavirus data through Cortellis Drug Discovery Intelligence, which offers the broadest and deepest sources of R&D intelligence. This includes drug pipelines, disease briefings, experimental pharmacology, pharmacokinetics, animal models, targets and more to assist research into the coronaviruses. Request access here.
We will continue to update you with additional resources and information as they become available.